Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Caffeine Versus Placebo for Spinal Headaches

This study has been completed.
Information provided by (Responsible Party):
Mark Kostic, United States Naval Medical Center, Portsmouth Identifier:
First received: December 16, 2008
Last updated: October 28, 2013
Last verified: October 2013
Caffeine will be studied against placebo in patients with positional headache after a lumbar puncture (aka "spinal headache").

Condition Intervention
Post Dural Puncture Headache
Drug: Caffeine
Drug: saline

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Trial of IV Caffeine vs Placebo for Post-Dural-Puncture Headache in the Emergency Department

Resource links provided by NLM:

Further study details as provided by United States Naval Medical Center, Portsmouth:

Primary Outcome Measures:
  • Pain as measured by Visual Analog Scale [ Time Frame: 60 minutes ]

Enrollment: 21
Study Start Date: January 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
IV caffeine with saline and opiate
Drug: Caffeine
Caffeine 500 mg IV
Other Name: Treatment group
Placebo Comparator: 2
IV saline with opiate
Drug: saline
Normal saline
Other Name: Placebo control group

Detailed Description:
Pain will be assessed at set intervals using a Visual Analog Scale. Blood patch therapy will be offered to all those still in pain at the end of one hour after drug administration.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosed with post dural puncture headache

Exclusion Criteria:

  • age < 18
  • pregnant
  • allergic to caffeine
  • cardiac or peripheral vascular disease
  • uncontrolled hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00809627

United States, Virginia
Emergency Department, Naval Medical Center Portsmouth
Portsmouth, Virginia, United States, 23708
Sponsors and Collaborators
United States Naval Medical Center, Portsmouth
Study Chair: Mark A Kostic, MD United States Naval Medical Center, Portsmouth
Principal Investigator: Marcelo Darabos, MD United States Naval Medical Center, Portsmouth
  More Information

Responsible Party: Mark Kostic, Faculty physician, United States Naval Medical Center, Portsmouth Identifier: NCT00809627     History of Changes
Other Study ID Numbers: CIP 2006 0051
Study First Received: December 16, 2008
Last Updated: October 28, 2013

Keywords provided by United States Naval Medical Center, Portsmouth:

Additional relevant MeSH terms:
Post-Dural Puncture Headache
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Headache Disorders, Secondary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents processed this record on April 28, 2017